enGene (NASDAQ:ENGN) Stock: Insider William Grossman Buys 5,102 Shares

enGene Holdings Inc. (NASDAQ:ENGN) insider William Grossman purchased 5,102 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was bought at an average cost of $1.97 per share, for a total transaction of $10,050.94. Following the acquisition, the insider directly owned 5,102 shares in the company, valued at approximately $10,050.94. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

enGene Price Performance

Shares of enGene stock traded down $0.08 on Thursday, hitting $1.92. 794,213 shares of the company traded hands, compared to its average volume of 984,493. enGene Holdings Inc. has a 12-month low of $1.40 and a 12-month high of $12.25. The company has a current ratio of 10.21, a quick ratio of 10.21 and a debt-to-equity ratio of 0.11. The company has a market cap of $128.67 million, a P/E ratio of -1.70 and a beta of -0.28. The firm’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $3.44.

enGene (NASDAQ:ENGN) last announced its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Analysts expect that enGene Holdings Inc. will post -1.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ENGN. Citigroup reiterated a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Citizens Jmp reissued a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research report on Thursday, June 18th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of enGene in a research note on Tuesday, September 8th. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $11.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP purchased a new position in shares of enGene in the first quarter worth about $251,000. Sei Investments Co. bought a new stake in shares of enGene in the 1st quarter valued at about $409,000. Renaissance Technologies LLC boosted its holdings in enGene by 651.1% during the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after acquiring an additional 135,318 shares during the period. SR One Capital Management LP bought a new position in enGene during the 2nd quarter worth approximately $1,293,607. Finally, Elmind Capital LP bought a new position in enGene during the 4th quarter worth approximately $1,896,000. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.